The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial DOI Creative Commons
Kelli M. Richardson, Susan M. Schembre, Michelle R Jospe

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Abstract Aims To evaluate changes in dietary intake following liraglutide treatment, compared to dietitian‐supported caloric restriction and a weight‐neutral control, assess against nutrition recommendations. Materials Methods Participants with obesity prediabetes were randomly assigned 2:1:1 (1.8 mg/day), (−390 kcals/day) or dipeptidyl peptidase‐4 inhibitor (100 mg/day) for 14 weeks. Dietary was assessed via single 24‐h recall pre‐ postintervention. Within‐group between‐group differences macronutrient micronutrient intake, diet quality food sources evaluated, the proportion of participants meeting recommendations calculated. Results Seventy (69% female, 83% white) included. Average age 49.4 ± 11.3 years, mean BMI 39.5 6.1 kg/m 2 . Significant change percent calories from protein ( p = 0.037), carbohydrates 0.019) added sugar 0.002) observed across groups, those group having greatest increase decreases sugar. Micronutrient did not significantly differ between groups nor Total Healthy Eating Index (HEI)‐2020 scores. However, improved their HEI component score when adjusted baseline intake. Despite treatment group, failed meet several same recommendations, including fruit, vegetable dairy Conclusions Overall poor all groups. reduced its highlighting potential benefit counselling may have AOM users. Future research is needed examine long‐term impact use on without guidance, better inform clinical

Language: Английский

Medications for Obesity DOI
Kimberly A. Gudzune,

Robert F. Kushner

JAMA, Journal Year: 2024, Volume and Issue: 332(7), P. 571 - 571

Published: Aug. 20, 2024

Obesity affects approximately 19% of women and 14% men worldwide is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite significantly improve outcomes, such as type 2 diabetes, hypertension, dyslipidemia.

Language: Английский

Citations

58
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases DOI Creative Commons
Yehuda Handelsman,

John E. Anderson,

George L. Bakris

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 159, P. 155931 - 155931

Published: June 7, 2024

Language: Английский

Citations

24
Nutritional considerations with antiobesity medications DOI Creative Commons
Jaime P. Almandoz, Thomas A. Wadden, Colleen Tewksbury

et al.

Obesity, Journal Year: 2024, Volume and Issue: 32(9), P. 1613 - 1631

Published: June 10, 2024

The improved efficacy and generally favorable safety profile of recently approved emerging antiobesity medications (AOMs), which result in an average weight reduction ≥15%, represent significant advancement the treatment obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, monitoring patients treated with AOMs. Prior treatment, clinicians can identify preexisting risk factors counsel their on recommended intakes protein, dietary fiber, micronutrients, fluids. During AOMs, ongoing facilitate early recognition management gastrointestinal symptoms or inadequate nutrient fluid intake. Attention should also be paid other that impact response quality life, such as physical activity social emotional health. In context play active role supporting obesity improve health well-being promote optimal medical outcomes.

Language: Английский

Citations

24
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology DOI Creative Commons

Thomas A. Wadden,

Gregory K. Brown,

Christina Egebjerg

et al.

JAMA Internal Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 3, 2024

Importance Obesity is associated with numerous psychosocial complications, making psychiatric safety a consideration for treating people obesity. Few studies have investigated the of newly available antiobesity medications. Objective To evaluate subcutaneous semaglutide, 2.4 mg, once weekly in without known major psychopathology. Design, Setting, and Participants This post hoc analysis pooled data from randomized, double-blind, placebo-controlled, multicenter phase 3a STEP 1, 2, 3 trials (68 weeks; 2018-2020) 3b 5 trial (104 2018-2021) included adults overweight or obesity; 2 participants also had type diabetes. Trial designs been published previously. Interventions Semaglutide, vs placebo. Main Outcomes Measures Depressive symptoms suicidal ideation/behavior were assessed using Patient Health Questionnaire (PHQ-9) Columbia–Suicide Severity Rating Scale, respectively. Psychiatric nervous system disorder adverse events investigated. Results 3377 (2360 women [69.6%]; mean [SD] age, 49 [13] years) 304 (236 [77.6%]; 47 [11] years). In trials, (SD) baseline PHQ-9 scores placebo groups 2.0 (2.3) 1.8 (2.3), respectively, indicating no/minimal depression. at week 68 (2.9) (3.3), respectively; estimated treatment difference (95% CI) between was −0.56 (−0.81 to −0.32) ( P < .001). treated semaglutide less likely shift (from 68) more severe category depression (odds ratio, 0.63; 95% CI, 0.50-0.79; Based on 1% fewer reported during treatment, no differences generally balanced groups. Similar results observed 5. Conclusions Relevance The this suggest that did not increase risk developing small but statistically significant reduction depressive (not considered clinically meaningful). People obesity should be monitored mental health concerns so they can receive appropriate support care. Registration ClinicalTrials.gov Identifiers: 1 NCT03548935 ), NCT03552757 NCT03611582 NCT03693430 )

Language: Английский

Citations

18
Poor muscle quality: A hidden and detrimental health condition in obesity DOI
Flávio Teixeira Vieira,

Yaojun Cai,

Marı́a Cristina González

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

Language: Английский

Citations

2
Approach to Obesity Treatment in Primary Care DOI
Susan Z. Yanovski, Jack A. Yanovski

JAMA Internal Medicine, Journal Year: 2024, Volume and Issue: 184(7), P. 818 - 818

Published: March 11, 2024

Importance More than 40% of US adults have obesity, which increases the risks for multiple chronic diseases and premature mortality. Historically, nonsurgical interventions often not led to sufficient weight loss maintenance improve health, but highly effective antiobesity medications (AOMs) recently become available, additional therapeutics are under development. Given that most medical care with obesity is delivered in primary settings, guidance integrating weight-management approaches needed. Observations Lifestyle can lead a mean 2% 9% initial at 1 year increase likelihood 5% or more, regain over time common even continued treatment. Adjunctive treatments, including AOMs surgical approaches, larger, more sustained improvements numerous obesity-associated conditions. Highly AOMs, nutrient-stimulated hormone-based therapies, induce 15% more. Barriers intervention, access care, disproportionate influence on populations affected by its consequences. Conclusions Relevance Primary clinicians play vital role assessment, management, support patients obesity. With careful clinical assessment shared decision-making, flexible treatment plan be developed reflects evidence efficacy, patient preference, feasibility implementation. therapies lifestyle interventions, pharmacotherapeutics offer hope potential considerable health quality life.

Language: Английский

Citations

15
Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement DOI
John M. Jakicic, Caroline M. Apovian, Daheia J. Barr‐Anderson

et al.

Medicine & Science in Sports & Exercise, Journal Year: 2024, Volume and Issue: 56(10), P. 2076 - 2091

Published: Sept. 15, 2024

ABSTRACT Excessive body weight and adiposity contribute to many adverse health concerns. The American College of Sports Medicine (ACSM) recognizes that the condition excess is complex, with numerous factors warranting consideration. ACSM published a position stand on this topic in 2001 an update 2009, consensus paper role physical activity prevention gain 2019. This current serves as additional those prior papers. supports inclusion medical treatments (pharmacotherapy, metabolic bariatric surgery) adiposity, deemed be medically appropriate, provides perspectives within these therapies. For loss gain, effects may most prevalent when progressed appropriate manner at least 150 min·wk −1 moderate-intensity activity, benefits occur dose–response manner. High-intensity interval training does not appear superior moderate-to-vigorous for regulation, light-intensity also alternative approach provided it sufficient energy expenditure. Evidence support any one single mode other modes or loss, elicit holistic beyond multimodal should recommended. interaction between expenditure intake exercise control appetite are variable individuals. Physical interventions inclusive tailored sex, self-identified gender, race, ethnicity, socioeconomic status, age, developmental level. Intervention approaches can include different forms, channels, methods activity.

Language: Английский

Citations

12
Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs DOI Creative Commons
Sandra M. Christensen, Katie N. Robinson, Sara Thomas

et al.

Obesity Pillars, Journal Year: 2024, Volume and Issue: 11, P. 100121 - 100121

Published: July 25, 2024

Obesity and type 2 diabetes mellitus (T2DM) are increasingly common in the United States worldwide. Because both conditions associated with serious health consequences, weight reduction is recommended by professional medical nutrition societies to improve outcomes. Due striking efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like (GIP/GLP-1RAs) for glycemic control, there increased utilization patients obesity and/or T2DM. Yet, impact these medications on dietary intake less understood. This narrative literature review summarizes clinical studies quantifying characterizing people T2DM using GLP-1 or GIP/GLP-1 RAs. Though data from reveal that total caloric was reduced 16–39 %, few evaluated actual composition diet. Further research needed understand unique nutritional needs adults GIP/GLP-1RAs support development guidelines individuals.

Language: Английский

Citations

11
The past, present, and future of behavioral obesity treatment DOI
Ariana M. Chao,

Molly Moore,

Thomas A. Wadden

et al.

International Journal of Obesity, Journal Year: 2024, Volume and Issue: unknown

Published: April 27, 2024

Language: Английский

Citations

10
Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists DOI
Jamy D. Ard, Kristina H. Lewis, Justin B. Moore

et al.

JAMA, Journal Year: 2024, Volume and Issue: 332(1), P. 16 - 16

Published: May 14, 2024

Pat Hoddinott, MB, BS, PhD; Catriona O'Dolan, Lisa Macaulay, Stephan U. Dombrowski, James Swingler, MSc; Seonaidh Cotton, Alison Avenell, MD, BS; Abraham M. Getaneh, Cindy Gray, Kate Hunt, Frank Kee, MD; Alice MacLean, Michelle McKinley, Claire Torrens, Katrina Turner, Marjon van der Pol, Graeme MacLennan, MSc

Language: Английский

Citations

9